5,548 Shares in Zimmer Biomet Holdings, Inc. $ZBH Purchased by Empirical Financial Services LLC d.b.a. Empirical Wealth Management

Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the first quarter, HoldingsChannel.com reports. The firm purchased 5,548 shares of the medical equipment provider’s stock, valued at approximately $502,000.

Several other hedge funds have also recently bought and sold shares of the stock. DV Equities LLC bought a new stake in shares of Zimmer Biomet during the fourth quarter worth approximately $25,000. Monetary Solutions Ltd bought a new position in shares of Zimmer Biomet during the fourth quarter worth approximately $30,000. Gen Wealth Partners Inc acquired a new stake in Zimmer Biomet during the 4th quarter worth approximately $31,000. Flagship Harbor Advisors LLC bought a new stake in Zimmer Biomet in the 4th quarter valued at $32,000. Finally, Grove Bank & Trust boosted its stake in Zimmer Biomet by 431.6% in the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 328 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ZBH shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Monday, July 6th. Truist Financial restated a “hold” rating and issued a $92.00 price target (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. BMO Capital Markets initiated coverage on shares of Zimmer Biomet in a research report on Wednesday, July 8th. They set a “market perform” rating and a $95.00 price target on the stock. Canaccord Genuity Group set a $83.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Finally, Stifel Nicolaus cut their price objective on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $100.70.

Insider Buying and Selling at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the sale, the insider owned 27,251 shares in the company, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Stock Performance

ZBH opened at $91.18 on Friday. The firm has a market cap of $17.64 billion, a P/E ratio of 23.68, a price-to-earnings-growth ratio of 2.76 and a beta of 0.46. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. The business’s fifty day moving average is $87.17 and its 200-day moving average is $89.83.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The business had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. During the same quarter in the previous year, the firm earned $1.81 earnings per share. Zimmer Biomet’s revenue for the quarter was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is 24.94%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.